相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CURATE.AI: Optimizing Personalized Medicine with Artificial Intelligence
Agata Blasiak et al.
SLAS TECHNOLOGY (2020)
Identification of a synergistic combination of dimethylaminoparthenolide and shikonin alters metabolism and inhibits proliferation of pediatric precursor-B cell acute lymphoblastic leukemia
Shannon R. Sweeney et al.
MOLECULAR CARCINOGENESIS (2020)
Artificial intelligence in cancer therapy
Dean Ho
SCIENCE (2020)
Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma
Sanjay de Mel et al.
BLOOD CANCER JOURNAL (2020)
Metabolomics in acute myeloid leukemia
Anna V. Wojcicki et al.
MOLECULAR GENETICS AND METABOLISM (2020)
Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms
Michael Spinner et al.
BLOOD ADVANCES (2020)
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
Amy Burd et al.
NATURE MEDICINE (2020)
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Andrew H. Wei et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A Role for Lipid Mediators in Acute Myeloid Leukemia
Andreas Loew et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML
Christina D. Drenberg et al.
NATURE COMMUNICATIONS (2019)
Pre-Analytical Factors that Affect Metabolite Stability in Human Urine, Plasma, and Serum: A Review
Victoria L. Stevens et al.
METABOLITES (2019)
Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials
Jorge E. Cortes et al.
FUTURE ONCOLOGY (2019)
Artificial intelligence and big data facilitated targeted drug discovery
Benquan Liu et al.
STROKE AND VASCULAR NEUROLOGY (2019)
Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection
Hussein A. Abbas et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
Eytan M. Stein et al.
BLOOD (2019)
Shining a light on cell signaling in leukemia through proteomics: relevance for the clinic
Fieke W. Hoff et al.
EXPERT REVIEW OF PROTEOMICS (2018)
Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study
Ronan T. Swords et al.
LEUKEMIA RESEARCH (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
BCL-2 inhibition in AML: an unexpected bonus?
Marina Konopleva et al.
BLOOD (2018)
Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP)
Masturah Bte Mohd Abdul Rashid et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Functional genomic landscape of acute myeloid leukaemia
Jeffrey W. Tyner et al.
NATURE (2018)
Precision medicine in the treatment stratification of AML patients: challenges and progress
Ines Lohse et al.
Oncotarget (2018)
Modulating BET Bromodomain Inhibitor ZEN-3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform
Allan J. Pantuck et al.
ADVANCED THERAPEUTICS (2018)
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group
Lisa Pleyer et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Molecular targeting in acute myeloid leukemia
Seah H. Lim et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoidderived hematologic malignancies
Stephen E. Kurtz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time
Shumei Chia et al.
NATURE COMMUNICATIONS (2017)
High-throughput flow cytometry for drug discovery: principles, applications, and case studies
Mei Ding et al.
DRUG DISCOVERY TODAY (2017)
Targeting Metabolism for Cancer Therapy
Alba Luengo et al.
CELL CHEMICAL BIOLOGY (2017)
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia
Brittany Knick Ragon et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia
Bas J. Wouters et al.
BLOOD (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia
David B. Sykes et al.
CELL (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform
Ali Zarrinpar et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Development of ML390: A Human DHODH Inhibitor That Induces Differentiation in Acute Myeloid Leukemia
Timothy A. Lewis et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Mutations in AML: prognostic and therapeutic implications
Courtney D. DiNardo et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data
Karen A. Ryall et al.
BIOINFORMATICS (2015)
The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform
Amber Johnson et al.
DRUG DISCOVERY TODAY (2015)
A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value
Wen-Lian Chen et al.
BLOOD (2014)
A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome
Mark Kirschbaum et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Global phosphoproteome analysis of human bone marrow reveals predictive phosphorylation markers for the treatment of acute myeloid leukemia with quizartinib
C. Schaab et al.
LEUKEMIA (2014)
Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
Bhagwan Yadav et al.
SCIENTIFIC REPORTS (2014)
BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells
Eleni D. Lagadinou et al.
CELL STEM CELL (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical Properties
Michael P. Menden et al.
PLOS ONE (2013)
Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia
Tea Pemovska et al.
CANCER DISCOVERY (2013)
Phosphoproteomic Analysis of Leukemia Cells under Basal and Drug-treated Conditions Identifies Markers of Kinase Pathway Activation and Mechanisms of Resistance
Maria P. Alcolea et al.
MOLECULAR & CELLULAR PROTEOMICS (2012)
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Jay P. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Identification of prognostic protein biomarkers in childhood acute lymphoblastic leukemia (ALL)
Nan Jiang et al.
JOURNAL OF PROTEOMICS (2011)
DIGE-based proteomic analysis identifies nucleophosmin/B23 and nucleolin C23 as over-expressed proteins in relapsed/refractory acute leukemia
Jianda Hu et al.
LEUKEMIA RESEARCH (2011)
Impact of Genetic Features on Treatment Decisions in AML
Hartmut Doehner et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2011)
Novel Approaches to the Treatment of Acute Myeloid Leukemia
Gail J. Roboz
HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM (2011)
Arsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by Directly Binding PML
Xiao-Wei Zhang et al.
SCIENCE (2010)
Epigenetics in acute myeloid leukemia
Christoph Plass et al.
SEMINARS IN ONCOLOGY (2008)
Retinoic acid and arsenic for treating acute promyelocytic leukemia
GB Zhou et al.
PLOS MEDICINE (2005)
FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells
R Zheng et al.
BLOOD (2004)
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Y Yamamoto et al.
BLOOD (2001)
分享论文
